Mitchell G. Kluesner

1.4k total citations · 1 hit paper
12 papers, 769 citations indexed

About

Mitchell G. Kluesner is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Mitchell G. Kluesner has authored 12 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 2 papers in Epidemiology. Recurrent topics in Mitchell G. Kluesner's work include CRISPR and Genetic Engineering (9 papers), CAR-T cell therapy research (6 papers) and RNA Interference and Gene Delivery (2 papers). Mitchell G. Kluesner is often cited by papers focused on CRISPR and Genetic Engineering (9 papers), CAR-T cell therapy research (6 papers) and RNA Interference and Gene Delivery (2 papers). Mitchell G. Kluesner collaborates with scholars based in United States, Germany and Japan. Mitchell G. Kluesner's co-authors include Beau R. Webber, Branden S. Moriarity, Walker S. Lahr, Derek Nedveck, John Garbe, Juan E. Abrahante, Emily J. Pomeroy, Branden A. Smeester, Cara-lin Lonetree and Nicholas J. Slipek and has published in prestigious journals such as Nature Communications, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Mitchell G. Kluesner

12 papers receiving 753 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EditR: A Method to Quantify Base Editing from Sanger Sequencing

2018 314 citations Mitchell G. Kluesner, Derek Nedveck et al. The CRISPR Journal profile →

Peers

Countries citing papers authored by Mitchell G. Kluesner

Since Specialization

Citations

This map shows the geographic impact of Mitchell G. Kluesner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell G. Kluesner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell G. Kluesner more than expected).

Fields of papers citing papers by Mitchell G. Kluesner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell G. Kluesner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell G. Kluesner. The network helps show where Mitchell G. Kluesner may publish in the future.

Co-authorship network of co-authors of Mitchell G. Kluesner

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell G. Kluesner. A scholar is included among the top collaborators of Mitchell G. Kluesner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell G. Kluesner. Mitchell G. Kluesner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), Mitchell G. Kluesner, Emily J. Pomeroy, Joseph G. Skeate, Nicholas J. Slipek, Walker S. Lahr, (unknown), (unknown), Jason Bell, Kendell Clement, (unknown), Kanut Laoharawee, (unknown), Beau R. Webber, Branden S. Moriarity	8
2	Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy 2025 ·Nature Cancer ·Sylvain Simon, (unknown), (unknown), Anusha Rajan, (unknown), (unknown), (unknown), Longhui Zeng, (unknown), Pınar Ataca Atilla, Jason P. Price, Mitchell G. Kluesner, Carla A. Jaeger-Ruckstuhl, Tamer B. Shabaneh, James M. Olson, Xiaolei Su, Stanley R. Riddell	6
3	1150 Non-virally engineered polyclonal gamma delta T cells exhibit potent anti-tumor activity in vivo 2024 ·Regular and Young Investigator Award Abstracts ·(unknown), (unknown), (unknown), (unknown), (unknown), Mitchell G. Kluesner, Andrew Crane, Jason Bell, (unknown), Joseph G. Skeate, M. J. Johnson, Branden S. Moriarity, Beau R. Webber	1
4	Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies 2022 ·The CRISPR Journal ·(unknown), (unknown), (unknown), Mitchell G. Kluesner, Tomoyuki Koga, Miller Huang, William A. Weiss, Logan G. Spector, David A. Largaespada, Branden S. Moriarity, Beau R. Webber	3
5	Correction of Fanconi Anemia Mutations Using Digital Genome Engineering 2022 ·International Journal of Molecular Sciences ·(unknown), Mitchell G. Kluesner, (unknown), Walker S. Lahr, (unknown), (unknown), Anthony P. DeFeo, (unknown), Kanut Laoharawee, John E. Wagner, Margaret L. MacMillan, Gregory M. Vercellotti, Jakub Tolar, Mark J. Osborn, R. Scott McIvor, Beau R. Webber, Branden S. Moriarity	5
6	CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells 2021 ·Nature Communications ·Mitchell G. Kluesner, Walker S. Lahr, Cara-lin Lonetree, Branden A. Smeester, Xiaohong Qiu, Nicholas J. Slipek, (unknown), (unknown), Emily J. Pomeroy, (unknown), (unknown), (unknown), (unknown), Beau R. Webber, Branden S. Moriarity	74
7	MultiEditR: The first tool for the detection and quantification of RNA editing from Sanger sequencing demonstrates comparable fidelity to RNA-seq 2021 ·Molecular Therapy — Nucleic Acids ·Mitchell G. Kluesner, (unknown), (unknown), Annette Arnold, (unknown), Marco Binder, Beau R. Webber, Branden S. Moriarity, Riccardo Pecori	13
8	216 Multiplex base editing of NK cell to enhance cancer immunotherapy 2021 ·Regular and Young Investigator Award Abstracts ·(unknown), Mitchell G. Kluesner, (unknown), Beau R. Webber, Branden S. Moriarity	2
9	A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy 2019 ·Molecular Therapy ·Emily J. Pomeroy, John Hunzeker, Mitchell G. Kluesner, Walker S. Lahr, Branden A. Smeester, (unknown), Cara-lin Lonetree, Kenta Yamamoto, Laura E. Bendzick, Jeffrey S. Miller, Melissa A. Geller, Bruce Walcheck, Martin Felices, Beau R. Webber, Timothy K. Starr, Branden S. Moriarity	139
10	Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors 2019 ·Nature Communications ·Beau R. Webber, Cara-lin Lonetree, Mitchell G. Kluesner, Matthew J. Johnson, Emily J. Pomeroy, Miechaleen D. Diers, Walker S. Lahr, (unknown), Nicholas J. Slipek, Branden A. Smeester, Klaus N. Lovendahl, Amber McElroy, Wendy R. Gordon, Mark J. Osborn, Branden S. Moriarity	155
11	EditR: A Method to Quantify Base Editing from Sanger Sequencing breakdown → 2018 ·The CRISPR Journal ·Mitchell G. Kluesner, Derek Nedveck, Walker S. Lahr, John Garbe, Juan E. Abrahante, Beau R. Webber, Branden S. Moriarity	314
12	Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays 2018 ·PLoS ONE ·Morito Kurata, Natalie K. Wolf, Walker S. Lahr, Madison T. Weg, Mitchell G. Kluesner, (unknown), (unknown), (unknown), Beau R. Webber, Branden S. Moriarity	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact